Prevalence of chronic kidney disease and associated factors among the Chinese population in Taian, China

BMC Nephrology

Xuebin Zhang²  Zhangshen Ran³  Chuaihai Wang²  Xiaoqing Feng²  Yanxia Lou¹  Lingyu Xue² 

[1] Department of Nephrology, Veterans Hospital, Taian 271000, Shandong Province, China;Department of Nephrology, the Affiliated Hospital of Taishan Medical University, No. 706 Taishan Street, Taian 271000, Shandong Province, China;The Physical Examination Centre of Affiliated Hospital of Taishan Medical University, Taian 271000, Shandong Province, China

关键词: Awareness;    Risk factors;    Prevalence;    Epidemiology;    Chronic kidney disease;   

Others  :  1122071
DOI  :  10.1186/1471-2369-15-205

 received in 2014-08-06, accepted in 2014-12-11,  发布年份 2014

【 摘 要 】

Background

This study was designed to assess the prevalence of chronic kidney disease (CKD) and associated risk factors among the Chinese population in Taian, China.

Methods

A primary care-based cross-sectional study was conducted in Taian, China, from September to December 2012. Participants selected by a multi-stage stratified cluster sampling procedure were interviewed and tested for hematuria, albuminuria, estimated glomerular filtration rate (eGFR) and other clinical indices. Factors associated with CKD were analyzed by univariate and multivariate logistic regression analysis.

Results

A total of 14,399 subjects were enrolled in this study. The rates of hematuria, albuminuria and reduced eGFR were 4.20%, 5.25% and 1.89%, respectively. Approximately 9.49% (95% CI: 8.93%–10.85%) of the participants had at least one indicator of CKD, with an awareness of 1.4%. Univariate analyses showed that greater age, body mass index, and systolic and diastolic blood pressure; higher levels of serum creatinine, uric acid, fasting blood glucose, triglycerides, total cholesterol and low-density lipoprotein cholesterol; and lower eGFR were associated with CKD (p < 0.05 each). Multivariate analysis showed that age, female gender, educational level, smoking habits, systolic blood pressure, and history of diabetes mellitus, hyperlipidemia, hypercholesterolemia and hyperuricemia were independent risk factors for CKD.

Conclusions

The prevalence of CKD in the primary care population of Taian, China, is high, although awareness is quite low. Health education and policies to prevent CKD are urgently needed among this population.

【 授权许可】

   
2014 Xue et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Trautmann A, Schmid-Grendelmeier P, Krüger K, Crameri R, Akdis M, Akkaya A, Bröcker E-B, Blaser K, Akdis CA: T cells and eosinophils cooperate in the induction of bronchial epithelial cell apoptosis in asthma. J Allergy Clin Immunol 2002, 109(2):329-337.
• [2]Hakemi MS: Chronic kidney disease epidemiology. Iran J Kidney Dis 2014, 8(4):261-262.
• [3]Zhang QL, Koenig W, Raum E, Stegmaier C, Brenner H, Rothenbacher D: Epidemiology of chronic kidney disease: results from a population of older adults in Germany. Prev Med 2009, 48(2):122-127.
• [4]Stauffer ME, Fan T: Prevalence of anemia in chronic kidney disease in the United States. PLoS One 2014, 9(1):e84943.
• [5]Mallett A, Patel C, Salisbury A, Wang Z, Healy H, Hoy W: The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia. Orphanet J Rare Dis 2014, 9:98. BioMed Central Full Text
• [6]Nugent RA, Fathima SF, Feigl AB, Chyung D: The burden of chronic kidney disease on developing nations: a 21st century challenge in global health. Nephron Clin Pract 2011, 118(3):c269-277.
• [7]Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X, Chen N, Zhang J, Hu Z, Liu F, Hong D, Ma L, Liu H, Zhou X, Chen J, Pan L, Chen W, Wang W, Li X, Wang H: Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 2012, 379(9818):815-822.
• [8]Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003, 41(1):1-12.
• [9]Carney EF: Chronic kidney disease: Paradoxical association between serum IL-10 levels and risk of cardiovascular events. Nat Rev Nephrol 2014, 10(7):362.
• [10]Kong X, Ma X, Cui M, Xu D: Association of clustering of major cardiovascular risk factors with chronic kidney disease in the adult population. Clin Nephrol 2014, 82(2):92-97.
• [11]Gomez-Huelgas R, Martinez-Castelao A, Artola S, Gorriz JL, Menendez E: Treatment of type 2 diabetes mellitus in patients with chronic kidney disease]. Med Clin (Barc) 2014, 142(2):85 e81-10.
• [12]Bingham CO 3rd, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS, Fitzgerald BJ, O'Brien K, Tershakovec AM: Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 2007, 46(3):496-507.
• [13]Allison SJ: Chronic kidney disease: ESRD risk in CKD patients with incident atrial fibrillation. Nat Rev Nephrol 2013, 9(3):125.
• [14]Bello AK, Nwankwo E, El Nahas AM: Prevention of chronic kidney disease: a global challenge. Kidney Int Suppl 2005, 98:S11-17.
• [15]Yang SH, Dou KF, Song WJ: Prevalence of diabetes among men and women in China. N Engl J Med 2010, 362(25):2425-2426. author reply 2426
• [16]Zhang L, Yuan Z, Maddock JE, Zou J, Zheng Z, Zhou W, Zheng H: Chronic disease prevalence and influencing factors among rural residents in Jiangxi. China Int Health 2014, 6(2):106-111.
• [17]Ingsathit A, Thakkinstian A, Chaiprasert A, Sangthawan P, Gojaseni P, Kiattisunthorn K, Ongaiyooth L, Vanavanan S, Sirivongs D, Thirakhupt P, Mittal B, Singh A, and the Thai-SEEK Group: Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant 2010, 25(5):1567-1575.
• [18]Chen W, Wang H, Dong X, He H, Liu Q, Luo N, Tan J, Lin J, Nie J, Mao H, Chen W, Yu X: Epidemiologic study of chronic kidney disease in Guangzhou urban area (in Chinese). Chin J Nephrol 2007, 23:147-151.
• [19]Guo L, Zhang L, Wang X, Zhang P, Zhao Q, Wang F, Wang H: Screening for chronic kidney disease in a village of Zhejiang province (in Chinese). Chin J Nephrol 2007, 23:152-156.
• [20]Zhang L, Zuo L, Xu G, Wang F, Wang M, Wang S, Lv J, Liu L, Wang H: Community-based screening for chronic kidney disease among populations older than 40 years in Beijing. Nephrol Dial Transplant 2007, 22(4):1093-1099.
• [21]Chen W, Wang H, Dong X, Liu Q, Mao H, Tan J, Lin J, Zhou F, Luo N, He H, Johnson R, Zhou S, Yu X: Prevalence and risk factors associated with chronic kidney disease in an adult population from southern China. Nephrol Dial Transplant 2009, 24(4):1205-1212.
• [22]Chen W, Liu Q, Wang H, Johnson RJ, Dong X, Li H, Ba S, Tan J, Luo N, Liu T, He H, Yu X: Prevalence and risk factors of chronic kidney disease: a population study in the Tibetan population. Nephrol Dial Transplant 2011, 26(5):1592-1599.
• [23]Zhang L, Zhang P, Wang F, Zuo L, Zhou Y, Shi Y, Li G, Jiao S, Liu Z, Liang W: Prevalence and factors associated with CKD: a population study from Beijing. Am J Kidney Dis 2008, 51(3):373-384.
• [24]Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY, and on behalf of the Chinese eGFR Investigation Collaboration: Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006, 17(10):2937-2944.
• [25]Bailey RA, Wang Y, Zhu V, Rupnow MF: Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes 2014, 7(1):415. BioMed Central Full Text
• [26]Jin S: The Tenth Report of the Chinese National Health and Nutrition Examination Survey—Nutrition and Health Status, 1st ed In. Beijing: People’s Medical Publishing House; 2008.
• [27]Liu LS: Epidemiology of hypertension and cardiovascular disease–China experience. Clin Exp Hypertens A 1990, 12(5):831-844.
• [28]Chidambaram N, Sethupathy S, Saravanan N, Mori M, Yamori Y, Garg AK, Chockalingam A: Relationship of Sodium and Magnesium Intakes to Hypertension Proven by 24-Hour Urianalysis in a South Indian Population. J Clin Hypertens (Greenwich) 2014, 16(8):581-586.
• [29]Xie Y, Chen X: Epidemiology, major outcomes, risk factors, prevention and management of chronic kidney disease in China. Am J Nephrol 2008, 28(1):1-7.
• [30]Mazzali M, Jefferson JA, Ni Z, Vaziri ND, Johnson RJ: Microvascular and tubulointerstitial injury associated with chronic hypoxia-induced hypertension. Kidney Int 2003, 63(6):2088-2093.
• [31]Singh AK, Farag YM, Mittal BV, Subramanian KK, Reddy SR, Acharya VN, Almeida AF, Channakeshavamurthy A, Ballal HS, P G, Issacs R, Jasuja S, Kirpalani AL, Kher V, Modi GK, Nainan G, Prakash J, Rana DS, Sreedhara R, Sinha DK, V SB, Sunder S, Sharma RK, Seetharam S, Raju TR, Rajapurkar MM: Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol 2013, 14:114. BioMed Central Full Text
• [32]Alsuwaida AO, Farag YM, Al Sayyari AA, Mousa D, Alhejaili F, Al-Harbi A, Housawi A, Mittal BV, Singh AK: Epidemiology of chronic kidney disease in the Kingdom of Saudi Arabia (SEEK-Saudi investigators) - a pilot study. Saudi J Kidney Dis Transpl 2010, 21(6):1066-1072.
• [33]Lu C, Schneider MT, Gubbins P, Leach-Kemon K, Jamison D, Murray CJ: Public financing of health in developing countries: a cross-national systematic analysis. Lancet 2010, 375(9723):1375-1387.
• [34]Wang F, Zhang L, Wang H: Awareness of CKD in China: a national cross-sectional survey. Am J Kidney Dis 2014, 63(6):1068-1070.
• [35]Hallan SI, Stevens P: Screening for chronic kidney disease: which strategy? J Nephrol 2010, 23(2):147-155.
• [36]Black C, Sharma P, Scotland G, McCullough K, McGurn D, Robertson L, Fluck N, MacLeod A, McNamee P, Prescott G, Smith C: Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess 2010, 14(21):1-184.